Grace Therapeutics Inc. (GRCE)
2.29
-0.01 (-0.43%)
At close: Mar 13, 2025, 3:05 PM
-0.43% (1D)
| Bid | 2.26 |
| Market Cap | 31.39M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -1.53 |
| PE Ratio (ttm) | -1.5 |
| Forward PE | -2.89 |
| Analyst | Buy |
| Ask | 2.56 |
| Volume | 17,119 |
| Avg. Volume (20D) | 86,379 |
| Open | 2.32 |
| Previous Close | 2.30 |
| Day's Range | 2.25 - 2.52 |
| 52-Week Range | 2.13 - 4.97 |
| Beta | 1.20 |
About GRCE
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 7, 2012
Employees 4
Stock Exchange NASDAQ
Ticker Symbol GRCE
Website https://www.acastipharma.com
Analyst Forecast
According to 1 analyst ratings, the average rating for GRCE stock is "Buy." The 12-month stock price forecast is $12, which is an increase of 424.50% from the latest price.
Stock Forecasts1 month ago
+8.33%
Grace Therapeutics shares are trading higher after...
Unlock content with
Pro Subscription
